Company / Working Capital
Charles River Laboratories Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$326.7M
FY2025
5-year range
$240.9M / $553.6M
FY2021-FY2025
Trend
-20.1%
vs FY2024
Sector context
#88 of 160
Health Care
What the data says
At $327M, Charles River Laboratories's working capital ranks #88 of 160 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $227M in FY2016 to $554M in FY2023.
Based on SEC 10-K filings.
$327M in FY2025 with a 5-year CAGR of -2.0%.
Declined from $554M to $327M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- -2.0%
- 10-Year CAGR
- -
Sector benchmark
#88 of 160 in Health CareTop 55% of 160This company $326.7M Sector average $757.1M
▼
-56.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.0%, indicating a declining trend.
- In FY2025, working capital decreased 20.1% year-over-year.
- Ranks #88 out of 160 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $326.7M | -20.1% |
| FY2024 | $409.0M | -26.1% |
| FY2023 | $553.6M | +59.3% |
| FY2022 | $347.4M | +44.2% |
| FY2021 | $240.9M | -33.3% |
| FY2020 | $361.4M | +16.1% |
| FY2019 | $311.1M | -8.4% |
| FY2018 | $339.6M | -6.5% |
| FY2017 | $363.1M | +59.8% |
| FY2016 | $227.2M | -8.2% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026